The investigational oral microbiome therapeutic SER-109 was found to be safe and effective for the prevention of recurrent CDI.
All articles by Brian Park, PharmD
The vaccine candidate contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with an adjuvant.
Publish Date
-
Latest News Your top articles for Thursday
For More Personalized News -
Haymarket Medical NetworkTop Picks
- Loading...
Continuing Medical Education (CME/CE) Courses